This study investigates advanced HER2 positive solid tumors. It explores a combination treatment using special immune cells and an oncolytic virus to see how well they work together against the cancer.
The study evaluates the safety and effectiveness of combining HER2 specific CAR T cells with an oncolytic virus. Researchers want to understand how these treatments work together and determine the best dose levels.
- Who can participate: Adults aged 18 and older with advanced HER2 positive solid tumors can participate. They must have measurable disease and a tumor site suitable for injection, having tried standard treatments without success.
- Study details: Participants will receive an injection of an investigational virus directly into a tumor. Later, they will receive an infusion of special immune cells. A placebo may be used in some parts of the study.
How understandable was the trial content above?
Hard to understand
Easy to understand